Cargando…

Intraperitoneal paclitaxel for patients with primary malignant peritoneal mesothelioma: a phase I/II dose escalation and safety study—INTERACT MESO

INTRODUCTION: Malignant peritoneal mesothelioma (MPM) is a rare, aggressive tumour arising primarily from the peritoneum. The only potentially curative treatment is cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). However, the majority of patients are not eligible...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Kooten, Job P, Dietz, Michelle V, Guchelaar, Niels A D, Brandt-Kerkhof, Alexandra R M, Koolen, Stijn L W, Burger, Jacobus W A, Mathijssen, Ron H J, Verhoef, Cornelis, Aerts, Joachim G J V, Madsen, Eva V E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Surgery
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226944/ https://www.ncbi.nlm.nih.gov/pubmed/35732399 http://dx.doi.org/10.1136/bmjopen-2022-062907

Ejemplares similares

Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial
por: de Boer, Nadine L, et al.
Publicado: (2019)

Nasogastric- vs. percutaneous gastrostomy tube for prophylactic gastric decompression after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
por: van Kooten, Job P., et al.
Publicado: (2021)

Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies
por: Guchelaar, Niels A. D., et al.
Publicado: (2023)

Adjuvant dendritic cell-based immunotherapy after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with malignant peritoneal mesothelioma: a phase II clinical trial
por: Dietz, Michelle V, et al.
Publicado: (2023)

Predictive Ability of C-Reactive Protein in Detecting Short-Term Complications After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Retrospective Cross-Sectional Study
por: van Kooten, Job P., et al.
Publicado: (2020)

The Impact of Low Skeletal Muscle Mass on Short- and Long-Term Outcomes After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
por: Dietz, Michelle V., et al.
Publicado: (2022)

Concomitant intraperitoneal and systemic chemotherapy for extensive peritoneal metastases of colorectal origin: protocol of the multicentre, open-label, phase I, dose-escalation INTERACT trial
por: de Boer, Nadine Leonie, et al.
Publicado: (2019)

Malignant Peritoneal Mesothelioma: Patterns of Care and Survival in the Netherlands: A Population-Based Study
por: de Boer, Nadine L., et al.
Publicado: (2019)

Survival Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in Patients with Synchronous Versus Metachronous Onset of Peritoneal Metastases of Colorectal Carcinoma
por: Dietz, Michelle V., et al.
Publicado: (2022)

Molecular alterations and potential actionable mutations in peritoneal mesothelioma: a scoping review of high-throughput sequencing studies
por: Dietz, M.V., et al.
Publicado: (2023)

Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: a population-based study
por: van Kooten, Job P, et al.
Publicado: (2022)

MesoGraph: Automatic profiling of mesothelioma subtypes from histological images
por: Eastwood, Mark, et al.
Publicado: (2023)

The Influence of Body Composition on the Systemic Exposure of Paclitaxel in Esophageal Cancer Patients
por: van Doorn, Leni, et al.
Publicado: (2021)

Effect of Scalp Cooling on the Pharmacokinetics of Paclitaxel
por: van Doorn, Leni, et al.
Publicado: (2021)

ASO Author Reflections: The Timing of Onset of Peritoneal Metastases from Colorectal Carcinoma Is Not an Independent Predictor of Survival Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
por: Dietz, Michelle V., et al.
Publicado: (2022)

Blood-based extracellular matrix biomarkers are correlated with clinical outcome after PD-1 inhibition in patients with metastatic melanoma
por: Hurkmans, Daan P, et al.
Publicado: (2020)

Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer
por: de Jong, Loek A. W., et al.
Publicado: (2023)

Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology
por: van der Kleij, Maud B. A., et al.
Publicado: (2023)

Induction of mesothelioma by intraperitoneal injections of ferric saccharate in male Wistar rats.
por: Okada, S., et al.
Publicado: (1989)

Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the treatment of malignant mesothelioma
por: Giger-Pabst, Urs, et al.
Publicado: (2018)

Extensive intrathoracic and intraperitoneal splenosis mimicking mesothelioma: a case report
por: Föh, Bandik, et al.
Publicado: (2022)

Recent Clinical Developments of Nanomediated Drug Delivery Systems of Taxanes for the Treatment of Cancer
por: van Eerden, Ruben A G, et al.
Publicado: (2020)

Characteristics and long‐term outcomes of advanced pleural mesothelioma in Latin America (MeSO‐CLICaP)
por: Rojas, Leonardo, et al.
Publicado: (2019)

Outcomes of multicystic peritoneal mesothelioma treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
por: Zahid, A, et al.
Publicado: (2020)

Study on the thermal stability of nab-paclitaxel during hyperthermic intraperitoneal chemotherapy
por: Zhang, Jingjing, et al.
Publicado: (2023)

Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival
por: Chiarucci, Carla, et al.
Publicado: (2020)

Malignant Pleural Mesothelioma: Preliminary Toxicity Results of Adjuvant Radiotherapy Hypofractionation in a Prospective Trial (MESO-RT)
por: Parisi, Elisabetta, et al.
Publicado: (2023)

Results of the Meso-ORIGINS feasibility study regarding collection of matched benign-mesothelioma tissue pairs by longitudinal surveillance
por: Ferguson, Katie, et al.
Publicado: (2023)

A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours
por: Bozionelou, V, et al.
Publicado: (2007)

Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program
por: Cantini, Luca, et al.
Publicado: (2020)

Does adding intraperitoneal paclitaxel to standard intraperitoneal regimen yield incremental survival? A propensity score-matched cohort study
por: Chang, Yen-Hou, et al.
Publicado: (2016)

Efficacy assessment of sustained intraperitoneal paclitaxel therapy in a murine model of ovarian cancer using bioluminescent imaging
por: Vassileva, V, et al.
Publicado: (2008)

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: patient selection and special considerations
por: Enomoto, Laura M, et al.
Publicado: (2019)

Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy
por: White, Michael G., et al.
Publicado: (2020)

Protocol for a prospective observational cohort study collecting data on demographics, symptoms and biomarkers in people with mesothelioma (ASSESS-meso)
por: Conway, Ruairi J H, et al.
Publicado: (2022)

Intraperitoneal Paclitaxel Is Useful as Adjuvant Chemotherapy for Advanced Gastric Cancer with Serosal Exposure
por: Kitayama, Joji, et al.
Publicado: (2014)

Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma
por: Belderbos, Robert A., et al.
Publicado: (2020)

Tissue Type Differences in ABCB1 Expression and Paclitaxel Tissue Pharmacokinetics in Patients With Esophageal Cancer
por: van Eerden, Ruben A. G., et al.
Publicado: (2021)

Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
por: Cantini, Luca, et al.
Publicado: (2020)

Mesos in action
por: Ignazio, Roger
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_dqsd174b83ufn0nuuikjbvnis8